Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.68
NVS's Cash to Debt is ranked higher than
60% of the 1153 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.14 vs. NVS: 0.68 )
NVS' s 10-Year Cash to Debt Range
Min: 0.25   Max: 3.39
Current: 0.68

0.25
3.39
Equity to Asset 0.56
NVS's Equity to Asset is ranked higher than
66% of the 957 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.59 vs. NVS: 0.56 )
NVS' s 10-Year Equity to Asset Range
Min: 0.51   Max: 0.65
Current: 0.56

0.51
0.65
Interest Coverage 15.75
NVS's Interest Coverage is ranked higher than
56% of the 618 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 236.52 vs. NVS: 15.75 )
NVS' s 10-Year Interest Coverage Range
Min: 13.56   Max: 30.91
Current: 15.75

13.56
30.91
F-Score: 6
Z-Score: 4.23
M-Score: -2.81
WACC vs ROIC
7.88%
12.52%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 21.35
NVS's Operating margin (%) is ranked higher than
91% of the 1102 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.08 vs. NVS: 21.35 )
NVS' s 10-Year Operating margin (%) Range
Min: 17.81   Max: 24.34
Current: 21.35

17.81
24.34
Net-margin (%) 18.51
NVS's Net-margin (%) is ranked higher than
92% of the 1102 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.34 vs. NVS: 18.51 )
NVS' s 10-Year Net-margin (%) Range
Min: 15.35   Max: 31.38
Current: 18.51

15.35
31.38
ROE (%) 14.30
NVS's ROE (%) is ranked higher than
84% of the 1128 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.08 vs. NVS: 14.30 )
NVS' s 10-Year ROE (%) Range
Min: 12.6   Max: 25.73
Current: 14.3

12.6
25.73
ROA (%) 8.13
NVS's ROA (%) is ranked higher than
83% of the 1163 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.54 vs. NVS: 8.13 )
NVS' s 10-Year ROA (%) Range
Min: 7.21   Max: 16.18
Current: 8.13

7.21
16.18
ROC (Joel Greenblatt) (%) 54.86
NVS's ROC (Joel Greenblatt) (%) is ranked higher than
92% of the 1158 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.77 vs. NVS: 54.86 )
NVS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 38.42   Max: 74.09
Current: 54.86

38.42
74.09
Revenue Growth (3Y)(%) -2.00
NVS's Revenue Growth (3Y)(%) is ranked higher than
60% of the 936 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.80 vs. NVS: -2.00 )
NVS' s 10-Year Revenue Growth (3Y)(%) Range
Min: -4.6   Max: 75.8
Current: -2

-4.6
75.8
EBITDA Growth (3Y)(%) 5.40
NVS's EBITDA Growth (3Y)(%) is ranked higher than
72% of the 833 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.60 vs. NVS: 5.40 )
NVS' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -7.6   Max: 84.9
Current: 5.4

-7.6
84.9
EPS Growth (3Y)(%) 6.00
NVS's EPS Growth (3Y)(%) is ranked higher than
76% of the 813 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.40 vs. NVS: 6.00 )
NVS' s 10-Year EPS Growth (3Y)(%) Range
Min: -7.2   Max: 84.1
Current: 6

-7.2
84.1
» NVS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

NVS Guru Trades in Q1 2014

Steven Cohen 12,821 sh (+50.30%)
Lee Ainslie 351,580 sh (+31.52%)
Sarah Ketterer 327,343 sh (+16.19%)
Bill Frels 4,105 sh (+15.47%)
HOTCHKIS & WILEY 2,302,956 sh (+10.87%)
Irving Kahn 28,068 sh (+2.56%)
Ken Fisher 5,889,287 sh (+1.77%)
John Buckingham 85,174 sh (+0.68%)
Murray Stahl 29,358 sh (+0.20%)
John Hussman 221,200 sh (unchged)
Pioneer Investments 85,400 sh (unchged)
Jean-Marie Eveillard 13,060 sh (unchged)
Dodge & Cox 46,441,169 sh (-0.10%)
Tweedy Browne 291,500 sh (-0.29%)
Mario Gabelli 10,740 sh (-0.92%)
RS Investment Management 76,544 sh (-4.38%)
PRIMECAP Management 24,014,586 sh (-10.13%)
Manning & Napier Advisors, Inc 314,309 sh (-12.67%)
Jim Simons 96,000 sh (-85.44%)
» More
Q2 2014

NVS Guru Trades in Q2 2014

Louis Moore Bacon 180,000 sh (New)
Dodge & Cox 51,102,219 sh (+10.04%)
Manning & Napier Advisors, Inc 332,704 sh (+5.85%)
Ken Fisher 5,969,963 sh (+1.37%)
Pioneer Investments 86,323 sh (+1.08%)
RS Investment Management 76,745 sh (+0.26%)
Murray Stahl 29,425 sh (+0.23%)
Jean-Marie Eveillard 13,060 sh (unchged)
Steven Cohen 69,500 sh (unchged)
Bill Frels 4,105 sh (unchged)
Lee Ainslie Sold Out
PRIMECAP Management 23,846,236 sh (-0.70%)
Tweedy Browne 288,825 sh (-0.92%)
John Buckingham 83,941 sh (-1.45%)
Sarah Ketterer 320,852 sh (-1.98%)
John Hussman 214,000 sh (-3.25%)
Mario Gabelli 10,240 sh (-4.66%)
Irving Kahn 26,368 sh (-6.06%)
HOTCHKIS & WILEY 649,519 sh (-71.80%)
Jim Simons 14,000 sh (-85.42%)
» More
Q3 2014

NVS Guru Trades in Q3 2014

Lee Ainslie 272,570 sh (New)
Ruane Cunniff 7,772 sh (New)
Jim Simons 285,900 sh (+1942.14%)
Irving Kahn 30,368 sh (+15.17%)
Bill Frels 4,331 sh (+5.51%)
Sarah Ketterer 334,171 sh (+4.15%)
Manning & Napier Advisors, Inc 344,881 sh (+3.66%)
Ken Fisher 6,015,233 sh (+0.76%)
John Buckingham 84,337 sh (+0.47%)
Pioneer Investments 86,502 sh (unchged)
John Hussman 214,000 sh (unchged)
Murray Stahl 29,425 sh (unchged)
Louis Moore Bacon Sold Out
Dodge & Cox 50,905,449 sh (-0.39%)
Mario Gabelli 10,190 sh (-0.49%)
Jean-Marie Eveillard 12,848 sh (-1.62%)
Tweedy Browne 283,983 sh (-1.68%)
PRIMECAP Management 22,239,448 sh (-6.74%)
RS Investment Management 59,008 sh (-23.11%)
Steven Cohen 21,400 sh (-69.21%)
HOTCHKIS & WILEY 9,646 sh (-98.51%)
» More
Q4 2014

NVS Guru Trades in Q4 2014

Jim Simons 860,800 sh (+201.08%)
Lee Ainslie 519,369 sh (+90.55%)
Manning & Napier Advisors, Inc 358,674 sh (+4.00%)
Irving Kahn 30,968 sh (+1.98%)
Sarah Ketterer 336,278 sh (+0.63%)
HOTCHKIS & WILEY 9,665 sh (+0.20%)
Jean-Marie Eveillard 12,848 sh (unchged)
Ruane Cunniff Sold Out
Steven Cohen Sold Out
Ken Fisher 6,007,365 sh (-0.13%)
Murray Stahl 29,367 sh (-0.20%)
PRIMECAP Management 22,168,678 sh (-0.32%)
Dodge & Cox 50,324,645 sh (-1.14%)
Bill Frels 4,280 sh (-1.18%)
John Buckingham 82,902 sh (-1.70%)
Pioneer Investments 82,942 sh (-4.12%)
Mario Gabelli 9,590 sh (-5.89%)
Tweedy Browne 266,037 sh (-6.32%)
John Hussman 164,000 sh (-23.36%)
RS Investment Management 3,000 sh (-94.92%)
» More
» Details

Insider Trades

Latest Guru Trades with NVS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 26.10
NVS's P/E(ttm) is ranked higher than
85% of the 1277 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 59.80 vs. NVS: 26.10 )
NVS' s 10-Year P/E(ttm) Range
Min: 7.87   Max: 26.66
Current: 26.1

7.87
26.66
Forward P/E 18.90
NVS's Forward P/E is ranked higher than
94% of the 1277 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. NVS: 18.90 )
N/A
PE(NRI) 23.90
NVS's PE(NRI) is ranked higher than
88% of the 1277 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 56.20 vs. NVS: 23.90 )
NVS' s 10-Year PE(NRI) Range
Min: 10.66   Max: 24.19
Current: 23.9

10.66
24.19
P/B 3.50
NVS's P/B is ranked higher than
70% of the 1277 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.10 vs. NVS: 3.50 )
NVS' s 10-Year P/B Range
Min: 1.69   Max: 4.14
Current: 3.5

1.69
4.14
P/S 4.63
NVS's P/S is ranked higher than
82% of the 1277 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.25 vs. NVS: 4.63 )
NVS' s 10-Year P/S Range
Min: 1.88   Max: 4.92
Current: 4.63

1.88
4.92
PFCF 24.60
NVS's PFCF is ranked higher than
89% of the 1277 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. NVS: 24.60 )
NVS' s 10-Year PFCF Range
Min: 7.03   Max: 26.95
Current: 24.6

7.03
26.95
POCF 18.76
NVS's POCF is ranked higher than
88% of the 1277 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 45.64 vs. NVS: 18.76 )
NVS' s 10-Year POCF Range
Min: 5.75   Max: 19.36
Current: 18.76

5.75
19.36
EV-to-EBIT 23.15
NVS's EV-to-EBIT is ranked higher than
84% of the 1277 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 40.16 vs. NVS: 23.15 )
NVS' s 10-Year EV-to-EBIT Range
Min: 8.9   Max: 23.2
Current: 23.15

8.9
23.2
Shiller P/E 25.10
NVS's Shiller P/E is ranked higher than
89% of the 1277 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. NVS: 25.10 )
NVS' s 10-Year Shiller P/E Range
Min: 9.22   Max: 25.87
Current: 25.1

9.22
25.87
Current Ratio 1.39
NVS's Current Ratio is ranked higher than
57% of the 1023 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.20 vs. NVS: 1.39 )
NVS' s 10-Year Current Ratio Range
Min: 1.04   Max: 2.83
Current: 1.39

1.04
2.83
Quick Ratio 1.17
NVS's Quick Ratio is ranked higher than
61% of the 1023 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.70 vs. NVS: 1.17 )
NVS' s 10-Year Quick Ratio Range
Min: 0.78   Max: 2.48
Current: 1.17

0.78
2.48
Days Inventory 139.62
NVS's Days Inventory is ranked higher than
69% of the 1277 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 139.62 vs. NVS: 139.62 )
NVS' s 10-Year Days Inventory Range
Min: 117.86   Max: 297.21
Current: 139.62

117.86
297.21
Days Sales Outstanding 58.31
NVS's Days Sales Outstanding is ranked higher than
82% of the 1277 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 89.57 vs. NVS: 58.31 )
NVS' s 10-Year Days Sales Outstanding Range
Min: 53.85   Max: 79.16
Current: 58.31

53.85
79.16

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 2.60
NVS's Dividend Yield is ranked higher than
94% of the 687 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.30 vs. NVS: 2.60 )
NVS' s 10-Year Dividend Yield Range
Min: 1.47   Max: 5.11
Current: 2.6

1.47
5.11
Dividend Payout 0.63
NVS's Dividend Payout is ranked higher than
93% of the 1277 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. NVS: 0.63 )
NVS' s 10-Year Dividend Payout Range
Min: 0.22   Max: 0.67
Current: 0.63

0.22
0.67
Dividend growth (3y) 6.80
NVS's Dividend growth (3y) is ranked higher than
78% of the 479 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.30 vs. NVS: 6.80 )
NVS' s 10-Year Dividend growth (3y) Range
Min: 0   Max: 18.5
Current: 6.8

0
18.5
Yield on cost (5-Year) 3.79
NVS's Yield on cost (5-Year) is ranked higher than
95% of the 694 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.54 vs. NVS: 3.79 )
NVS' s 10-Year Yield on cost (5-Year) Range
Min: 2.14   Max: 7.44
Current: 3.79

2.14
7.44
Share Buyback Rate -0.20
NVS's Share Buyback Rate is ranked higher than
82% of the 778 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -1.10 vs. NVS: -0.20 )
NVS' s 10-Year Share Buyback Rate Range
Min: 42.5   Max: -2.7
Current: -0.2

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 13.80
NVS's Price/Tangible Book is ranked lower than
51% of the 1277 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.50 vs. NVS: 13.80 )
NVS' s 10-Year Price/Tangible Book Range
Min: 0.16   Max: 35.33
Current: 13.8

0.16
35.33
Price/DCF (Projected) 1.60
NVS's Price/DCF (Projected) is ranked higher than
92% of the 1277 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. NVS: 1.60 )
NVS' s 10-Year Price/DCF (Projected) Range
Min: 0.76   Max: 1.53
Current: 1.6

0.76
1.53
Price/Median PS Value 1.50
NVS's Price/Median PS Value is ranked higher than
68% of the 1277 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.50 vs. NVS: 1.50 )
NVS' s 10-Year Price/Median PS Value Range
Min: 0.75   Max: 1.69
Current: 1.5

0.75
1.69
Price/Graham Number 3.70
NVS's Price/Graham Number is ranked higher than
77% of the 1277 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. NVS: 3.70 )
NVS' s 10-Year Price/Graham Number Range
Min: 0.07   Max: 4.84
Current: 3.7

0.07
4.84
Earnings Yield (Greenblatt) 4.30
NVS's Earnings Yield (Greenblatt) is ranked higher than
79% of the 1150 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.10 vs. NVS: 4.30 )
NVS' s 10-Year Earnings Yield (Greenblatt) Range
Min: 4.3   Max: 11.3
Current: 4.3

4.3
11.3
Forward Rate of Return (Yacktman) 1.35
NVS's Forward Rate of Return (Yacktman) is ranked higher than
69% of the 582 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.44 vs. NVS: 1.35 )
NVS' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 1.3   Max: 81.5
Current: 1.35

1.3
81.5

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:GSK, JNJ, PFE, RHHBY, ABT » details
Traded in other countries:0HKE.UK, NOVN.Switzerland, NVSEF.USA, NOT.Germany, NOTA.Germany, NVS N.Mexico, NVS.Argentina, NOVNEE.Switzerland,
Novartis AG was incorporated on February 29, 1996 under the Swiss laws. On December 20, 1996, its predecessor companies, Ciba-Geigy AG and Sandoz AG, merged into this new entity, creating Novartis. The Company is engaged in the research, development, manufacturing and marketing of healthcare and pharmaceuticals products. The Company's portfolio includes innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. The Company's wholly-owned businesses are organized into six global operating divisions, and they report teir results in the following five segments; Pharmaceuticals: Innovative patent-protected prescription medicines, Alcon: Surgical, ophthalmic pharmaceutical and vision care products, Sandoz: Generic pharmaceuticals, Vaccines and Diagnostics: Preventive human vaccines and blood testing diagnostics, Consumer Health: OTC (over-the-counter medicines) and Animal Health. The Pharmaceuticals division researches, develops, manufactures, distributes and sells patented prescription medicines and is organized in the following business franchises: Primary Care, consisting of Primary Care medicines and Established Medicines; and Specialty Care, consisting of Ophthalmology, Neuroscience, Integrated Hospital Care, and Critical Care medicines. The manufacture of the products is complex and heavily regulated by governmental health authorities, which means that supply is never guaranteed. If the Company or its third party suppliers fail to comply with applicable regulations then there could be a product recall or other shutdown or disruption of its production activities. The Company is subject to the laws of Switzerland, in particular Swiss company and securities laws, and to the securities laws of the United States as applicable to foreign private issuers of securities.
» More Articles for NVS

Headlines

Articles On GuruFocus.com
Amgen’s First Drug For Cardiovascular Disease Gets The Green Light Apr 17 2015 
Bristol-Myers Signs An Exclusive Pact In Gene Therapy For Treating Cardiovascular Disorders Apr 08 2015 
Biotech Momentum Indicators: Achaogen (AKAO), Novartis (NVS), VIVUS (VVUS) Apr 01 2015 
Pfizer In The Process Of Making Path Breaking Vaccine Mar 18 2015 
Anacor Pharmaceuticals’ Q4 Was A Solid One For Investors Mar 16 2015 
AbbVie Strikes The Biggest Deal For Treatment Of Cancer Mar 10 2015 
Arrowhead Research Making Headway In The RNAi Therapy Platform Mar 09 2015 
Novartis Goes A Step Forward In Treating Lung Cancer Mar 02 2015 
Novartis Gets FTC Nod To Buyout Glaxo Smithkline’s Cancer Drugs Feb 25 2015 
Can These Three BioTech Companies Make It Big? Feb 20 2015 


More From Other Websites
Novartis and Momenta Get FDA Nod For Generic Copaxone - Analyst Blog Apr 17 2015
FDA approves generic version of top-selling MS drug Copaxone Apr 17 2015
FDA approves generic version of top-selling MS drug Copaxone Apr 17 2015
Maverick Capital Increases Stake in Novartis Apr 17 2015
Momenta Pharmaceuticals Inc. (MNTA) in Focus: Stock Jumps 6.1% - Tale of the Tape Apr 17 2015
[video]Buy These 4 High-Yield Dividend Stocks to Take Advantage of the Health Care Boom Apr 17 2015
Aduro Biotech Establishes Major Collaboration with Novartis for Global Research, Development and... Apr 17 2015
Pfizer's Ibrance Study Stopped Early on Favorable Data - Analyst Blog Apr 16 2015
Bristol-Myers Deal Flags Three Gene-Therapy Picks Apr 16 2015
Momenta, Novartis Win FDA Nod For Generic Copaxone Apr 16 2015
FDA approves first generic version of Teva MS drug Copaxone Apr 16 2015
Exclusive: GlaxoSmithKline shutting Moon office; 274 employees affected Apr 16 2015
Sandoz receives FDA approval for GlatopaTM as the first generic competitor to MS therapy Copaxone®... Apr 16 2015
Receptos MS Drug Succeeds Against Ulcerative Colitis Apr 16 2015
2:02 am Novartis' Alcon receives FDA approval of new multifocal intraocular lens to treat cataract... Apr 16 2015
FDA approves new type of heart failure drug from Amgen Apr 15 2015
FDA approves new type of heart failure drug from Amgen Apr 15 2015
Biotech IPOs Ignite As Aduro Doubles On First Day Apr 15 2015
Pfizer, Biogen, AbbVie Get Good Drug-Trial News Apr 15 2015
3 Biotech Stocks Under $10 with Amazing Growth Prospects - Analyst Blog Apr 15 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK